| Trial ID: | L0054 |
| Source ID: | NCT00338000
|
| Associated Drug: |
Epoetin Alfa
|
| Title: |
EPO-BUL-01 - Study of the Optimization of Anemia Management of EPREX (Epoetin Alfa) in Predialysis Patients With Chronic Renal Failure
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Renal Failure
|
| Interventions: |
DRUG: Epoetin alfa
|
| Outcome Measures: |
Primary: Hemoglobin change - reach of target Hb levels (measured at Visit 1, 2, 3, 4) | Secondary: Prevention of left ventricular hypertrophy (measured at Visit 3 and 4)
|
| Sponsor/Collaborators: |
Sponsor: Janssen Pharmaceutica N.V., Belgium
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
292
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2001-06
|
| Completion Date: |
2005-05
|
| Results First Posted: |
|
| Last Update Posted: |
2011-02-01
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00338000
|
